[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer

Code:
80/2021
Title:
[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
Date:
Thursday 2nd December 2021
Author(s):
Sollini, M., Bartoli, F., Cavinato, L., Ieva, F., Ragni, A., Marciano, A., Zanca, R., Galli, L., Paiar, F., Pasqualetti , F. and Erba P. A.
Download link:
Abstract:
Background:The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions similarity in oligometastatic and plurimetastatic PCa, comparing the two most used definitions of oligometastatic disease.Methods:PCa patients eligible for [18F]FMCH PET/CT presenting biochemical failure after first-line curative treat-ments were invited to participate in this prospective observational trial. PET/CT images of 92 patients were visually and quantitatively analyzed. Each patient was classified as oligometastatic or plurimetastatic according to the total number of detected lesions (up to 3 and up to 5 or > 3 and > 5, respectively). Univariate and intra-patient lesions’ similarity analysis were performed.Results: [18F]FMCH PET/CT identified 370 lesions, anatomically classified as regional lymph nodes and distant metastases. Thirty-eight and 54 patients were designed oligometastatic and plurimetastatic, respectively, using a 3-lesion threshold. The number of oligometastic scaled up to 60 patients (thus 32 plurimetastatic patients) with a 5-lesion threshold. Similarity analysis showed high lesions’ heterogeneity. Grouping patients according to the number of metastases, patients with oligometastatic PCa defined with a 5-lesion threshold presented lesions heterogene-ity comparable to plurimetastic patients. Lesions within patients having a limited tumor burden as defined by three lesions were characterized by less heterogeneity.Conclusions:We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring dif-ferent cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometa-static PCa.
This report, or a modified version of it, has been also submitted to, or published on
EJNMMI Res. 2021 Nov 27;11(1):119.